Estrogens Modulate RANKL-RANK/Osteoprotegerin Mediated Interleukin-6 Effect on Thyrotoxicosis-related Bone Turnover in Mice

Abstract

Interleukin-6 has been shown to cause imbalance between bone resorption and formation in thyrotoxicosis. The aim of the present study was an attempt to estimate the influence of estrogens on thyrotoxicosis-related disturbances in bone turnover in relation to RANKL-RANK/osteoprotegerin system in IL-6 deficient mice. The study was performed on 56, 12–13 weeks old, female mice: C57BL/6J (wild-type; WT) and C57BL/6J^{IL6–/–Kopf} (IL-6 knock-out; IL6KO). The mice were randomly divided into 8 groups with 7 mice in each one: 1. WT controls, 2. IL6KO controls, 3. WT mice with thyrotoxicosis, 4. IL6KO mice with thyrotoxicosis, 5. WT ovariectomized, 6. IL6KO ovariectomized, 7. WT ovariectomized mice with thyrotoxicosis, and 8. IL6KO ovariectomized mice with thyrotoxicosis. Experimental model of menopause was evoked by bilateral ovariectomy carried out in 8–9 weeks old mice. Thyrotoxicosis was induced by intraperitoneal injection of levothyroxine at a dose of 1 μg/g daily over 21 days. The serum levels of TRACP5b, osteocalcin, OPG, and RANKL were determined by ELISA. RANKL serum concentrations were elevated significantly in all groups of ovariectomized mice as compared to respective controls, however, in a minor degree in IL6KO thyrotoxic mice as compared to wild-type animals. Osteoprotegerin serum levels were significantly increased in all thyrotoxic groups of mice except ovariectomized IL6KO animals. To sum up, the results of the present study suggest that IL-6 plays a key role in stimulation of RANKL-RANK/OPG system and this effect is strongly enhanced in conditions of accelerated bone turnover such as thyrotoxicosis and/or estrogen depletion.

Key words

sRANKL - OPG - IL-6 - hyperthyrosis - osteoporosis - IL-6 knock-out mice

References

• 1 Manolagas SC, Jilka RL. Bone marrow, cytokines and bone remodelling.  N Engl J Med. 1995;  332 305-311
• 2 Pacifici R. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis.  J Bone Miner Res. 1996;  8 1043-1051
• 3 Roodman GD. Paget's disease and osteoclast biology.  Exp J Hematol. 1996;  27 1229-1241
• 4 Poli V, Balena R, Fattori E, Markatos A, Yamamoto M, Tanaka H, Ciliberto G, Rodan GA, Costantini F. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion.  EMBO J. 1994;  13 1189-1196
• 5 Hayashi M, Rho MC, Enomoto A, Fukami A, Kim YP, Kikuchi Y, Sunazuka T, Hirose T, Komiyama K, Omura S. Suppression of bone resorption by madindoline A, a novel nonpeptide antagonist to gp130.  Proc Natl Acad Sci USA. 2002;  12 14728-14733
• 6 Murphy E, Williams GR. The thyroid and the skeleton.  Clin Endocrinol. 2004;  61 285-298
• 7 Grimnes G, Emaus N, Joakimsen RM, Figenschau Y, Jorde R. The relationship between serum TSH and bone mineral density in men and postmenopausal women: the Tromsø study.  Thyroid. 2008;  18 1147-1155
• 8 Mysliwiec J, Zbucki R, Winnicka M, Sawicki B, Nikolajuk A, Kaminski K, Mysliwiec P, Musial W, Bondyra Z, Walecki J, Gorska M. A crucial role of interleukin-6 in the pathogenesis of thyrotoxicosis-related disturbances of bone turnover in mice.  Horm Metab Res. 2007;  39 1-5
• 9 O’Brien CA, Jilka RL, Fu Q, Stewart S, Weinstein RS, Manolagas SC. IL-6 is not required for parathyroid hormone stimulation of RANKL expression, osteoclast formation, and bone loss in mice.  Am J Physiol Endocrinol Metab. 2005;  289 E784-E793
• 10 Sims NA, Jenkins BJ, Quinn JM, Nakamura A, Glatt M, Gillespie MT, Ernst M, Martin TJ. Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways.  J Clin Invest. 2004;  113 379-389
• 11 O’Brien CA, Gubrij I, Lin SC, Saylors RL, Manolagas SC. STAT3 activation in stromal osteoblastic cells is required for induction of the receptor activator of NF-κB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D₃ or parathyroid hormone.  J Biol Chem. 1999;  274 19301-19308
• 12 Liu XH, Kirschenbaum A, Yao S, Levine AC. Interactive effect of interleukin-6 and prostaglandin E2 on osteoclastogenesis via the OPG/RANKL/RANK system.  Ann N Y Acad Sci. 2006;  1068 225-233
• 13 van Tuyl LH, Voskuyl AE, Boers M, Geusens P, Landewé RB, Dijkmans BA, Lems WF. Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis.  Ann Rheum Dis. 2010;  69 1623-1628
• 14 Sivagurunathan S, Muir MM, Brennan TC, Seale JP, Mason RS. Influence of glucocorticoids on human osteoclast generation and activity.  J Bone Miner Res. 2005;  20 390-398
• 15 Paternoster L, Ohlsson C, Sayers A, Vandenput L, Lorentzon M, Evans DM, Tobias JH. OPG and RANK Polymorphisms Are Both Associated with Cortical Bone Mineral Density: Findings from a Metaanalysis of the Avon Longitudinal Study of Parents and Children and Gothenburg Osteoporosis and Obesity Determinants Cohorts.  J Clin Endocrinol Metab. 2010;  95 3940-3948
• 16 Shevde NK, Bendixen AC, Dienger KM, Pike JW. Estrogens suppress RANK-ligand induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression.  PNAS. 2000;  97 7829-7834
• 17 Shu L, Guan SM, Fu SM, Guo T, Cao M, Ding Y. Estrogen modulates cytokine expression in human periodontal ligament cells.  J Dent Res. 2008;  87 142-147
• 18 Kodama I, Niida S, Sanada M, Yoshiko Y, Tsuda M, Maeda N, Ohama K. Estrogen regulates the production of VEGF for osteoclast formation and activity in op/op mice.  J Bone Mineral Res. 2004;  19 200-206
• 19 Fuller K, Wong B, Fox S, Choi Y, Chambers TJ. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts.  J Exp Med. 1998;  188 997-1001
• 20 Giner M, Montoya MJ, Vázquez MA, Rios MJ, Moruno R, Miranda MJ, Pérez-Cano R. Modifying RANKL/OPG mRNA expression in differentiating and growing human primary osteoblasts.  Horm Metab Res. 2008;  40 869-874
• 21 Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.  Cell. 1998;  93 165-176
• 22 Jimi E, Akiyama S, Tsurukai T, Okahashi N, Kobayashi K, Udagawa N, Nishihara T, Takahashi N, Suda T. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function.  J Immunol. 1999;  163 434-442
• 23 Blair JM, Zheng Y, Dunstan CR. RANK ligand.  Int J Biochem Cell Biol. 2007;  39 1077-1081
• 24 Bolon B, Carter C, Daris M, Morony S, Capparelli C, Hsieh A, Mao M, Kosteniuk P, Dunstan CR, Lacey DL, Sheng JZ. Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis.  Mol Ther. 2001;  3 197-205
• 25 Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women.  J Clin Invest. 2003;  111 1221-1230
• 26 Han KO, Choi JT, Choi HA, Moon IG, Yim CH, Park WK, Yoon HK, Han IK. The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone.  Clin Endocrinol (Oxf). 2005;  62 349-353
• 27 Rogers A, Saleh G, Hannon RA, Greenfield D, Eastell R. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women.  J Clin Endocrinol Metab. 2002;  87 4470-4475
• 28 Riggs BL, Khosla S, Atkinson EJ, Dunstan CR, Melton 3rd LJ. Evidence that type I osteoporosis results from enhanced responsiveness of bone to estrogen deficiency.  Osteoporos Int. 2003;  14 728-733
• 29 Jorgensen HL, Kusk P, Madsen B, Fenger M, Lauritzen JB. Serum osteoprotegerin (OPG) and the A163G polymorphism in the OPG promoter region are related to peripheral measures of bone mass and fracture odds ratios.  J Bone Miner Metab. 2004;  22 132-138
• 30 Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Koukoulis G, Kita M, Avramidis A. Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial.  Horm Metab Res. 2008;  40 281-285
• 31 Lee JS, Ryu CH, Moon NH, Kim SJ, Park SY, Suh KT. Changes in serum levels of receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, IL-6 and TNF-alpha in patients with a concomitant head injury and fracture.  Arch Orthop Trauma Surg. 2009;  129 711-718
• 32 Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women.  J Clin Endocrinol Metab. 2001;  86 631-637
• 33 Schett G, Kiechl S, Redlich K, Oberhollenzer F, Weger S, Egger G, Mayr A, Jocher J, Xu Q, Pietschmann P, Teitelbaum S, Smolen J, Willeit J. Soluble RANKL and risk of nontraumatic fracture.  JAMA. 2004;  291 1108-1113

Correspondence